Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
The stock has since recovered and at recent prices was up 47% for the year. Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near term from this popular stock. Iovance could expand Amtagvi to new patients Iovance Biotherapeutics stock more than doubled in February after the Food and Drug Administration approved Amtagvi, its first drug. Amtagvi is a complicated cellular therapy made of tumor-infiltrating lymphocytes (TILs), a type of immune cell that recognizes and attacks cancer cells. At the moment, Amtagvi is approved to treat patients with unresectable or metastatic melanoma that failed to respond or relapsed after treatment with a PD-1 blocking antibody such as Keytruda from Merck Second-quarter sales of Amtagvi plus Proleukin, an immune cell growth factor that Iovance sells to expand the presence of infused TILs, reached just $31.1 million. This is a good start for a new cancer th
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial OfficerGlobeNewswire
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Piper Sandler from $10.00 to $7.50. They now have a "neutral" rating on the stock.MarketBeat
- What's Wrong With Iovance Biotherapeutics Stock? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 11/7/24 - Beat
IOVA
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form 4
- 2/12/25 - Form 3
- IOVA's page on the SEC website